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Abstract
Background and Objective Activity of human cyto-
chrome P450 enzymes (CYPs) shows high inter-and intra-
individual variability, which is determined by genetic and
non-genetic factors. Using a combination of CYP-specific
probe drugs, phenotyping cocktails allow simultaneous
assessment of the activity of different CYP isoforms. The
objective of this study was to characterize the phenotyping
metrics of the Basel cocktail in healthy male subjects with
induced and inhibited CYP activity.
Methods In a randomized crossover study, the probe
drugs for simultaneous phenotyping of CYP1A2 (caf-
feine), CYP2B6 (efavirenz), CYP2C9 (losartan), 2C19
(omeprazole), CYP2D6 (metoprolol), and CYP3A4 (mi-
dazolam) were administered to 16 subjects without pre-
treatment (baseline), after pretreatment with a combination
of CYP inhibitors (ciprofloxacin, ketoconazole, and
paroxetine), and after CYP induction with rifampicin. All
subjects were genotyped. Pharmacokinetic profiles of the
probe drugs and their main metabolites and metabolic
ratios 2, 4, 6, and 8 h after probe drug application were
determined in plasma and compared with the correspond-
ing area under the plasma concentration-time curve (AUC)
ratios.
Results The Basel phenotyping cocktail was well toler-
ated by all subjects independent of pretreatment. Good
correlations of metabolic ratios with AUC ratios of the
corresponding probe drugs and their metabolites for all
three conditions (baseline, CYP inhibition, and CYP
induction) were found at 2 h after probe drug administra-
tion for CYP3A4, at 4 h for CYP1A2 and CYP2C19, and at
6 h for CYP2B6 and CYP2D6. While CYP inhibition
significantly changed AUC ratios and metabolic ratios at
these time points for all six CYP isoforms, CYP induction
did not significantly change AUC ratios for CYP2C9. For
CYP3A4, total 10-hydroxymidazolam concentrations after
pretreatment of samples with b-glucuronidase were needed
to obtain adequate reflection of CYP induction by the
metabolic ratio.
Conclusions Inhibition of CYP activity can be detected
with the Basel phenotyping cocktail for all six tested CYP
isoforms at the proposed time points. The AUC ratio of
losartan:losartan carboxylic acid in plasma does not seem
suitable to detect induction of CYP2C9. The observed
metabolic ratios for inhibited and induced CYP activity
need to be confirmed for extensive metabolizers, and typ-
ical ratios for subjects with genetically altered CYP activity
will need to be established in subsequent studies.
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Key Points
Extensive validation data are required before new
phenotyping cocktails can be introduced into clinical
practice.
In this study, the phenotyping metrics of the recently
introduced Basel phenotyping cocktail were
characterized in healthy subjects with inhibited and
induced cytochrome P450 enzyme (CYP) activity.
While CYP inhibition could be reliably detected for
all tested isoforms, detection of CYP induction was
more challenging, requiring e.g., the use of total
10-hydroxymidazolam concentrations to obtain
metabolic ratios that adequately reflect induced
CYP3A4 activity.
1 Introduction
Human cytochrome P450 enzymes (CYPs) are responsible
for oxidative metabolism of approximately 50 % of com-
monly used drugs and many endogenous compounds. Inter-
and intra-individual CYP activity is highly variable and
determined by multiple factors, such as genetic variants,
endogenous mediators, and environmental influences [1].
While genetic factors can be assessed by genotyping, the
net effect of all influencing factors on CYP activity can
only be assessed by phenotyping.
With the cocktail approach, the activity of several CYP
isoforms can be simultaneously assessed by administration
of a combination of CYP-specific probe drugs. Several
phenotyping cocktails have been published to date. How-
ever, many have only been tested in subjects with normal
CYP activity and data on the phenotyping metrics from
systematic studies with inhibited and/or induced CYP
function are only available for some of these cocktails [2–
6].
Studying a phenotyping cocktail in subjects with altered
CYP activity is an essential part of the validation process.
CYP induction or inhibition will lead to very low con-
centrations of the probe drug or its metabolite, and highly
sensitive bioanalytical methods are required to obtain a
reliable phenotyping metric. Such studies will also provide
a typical range of values for low or high CYP activity for
each phenotyping metric, which can serve as a reference
for future applications of the cocktail.
We recently have developed a new phenotyping cocktail
for six major CYP isoforms [7]. Our cocktail is based on
low-dose probe drugs that are widely used in clinical
practice and easily available on the market. We showed
that the new combination of probe drugs can be used
without mutual interactions and without causing relevant
adverse effects. In subjects without inhibited or induced
CYP activity, metabolic ratios (i.e., concentration ratio of
probe drug and CYP-specific metabolite) determined in a
single blood sample correlated well with area under the
plasma concentration-time curve (AUC) ratios of the probe
drugs and their metabolites. The goal of the current study
was to characterize the phenotyping metrics of our cocktail
in healthy male subjects after pretreatment with a combi-
nation of CYP inhibitors and a CYP inducer. This is an




A single-center, randomized, two-way crossover study
(ClinicalTrials.gov ID: NCT01386593) was performed at
the Phase I Research Unit, University Hospital Basel,
Switzerland. Healthy, male non-smoking Caucasian sub-
jects without clinically significant findings on physical
examination, routine laboratory, and electrocardiogram
(ECG) evaluations were included to limit confounding
influences of ethnicity and sex on drug metabolism. Use of
herbal medicines, over-the-counter medications, or food
products known to be inducers or inhibitors of CYP450
(e.g., grapefruit juice) was forbidden during the entire
study. Consumption of alcoholic- and caffeine-containing
beverages was not allowed for 72 h prior to dosing until
after the last sampling time point of the study period. Probe
drugs of the Basel cocktail [7] (100 mg caffeine, 50 mg
efavirenz, 12.5 mg losartan, 10 mg omeprazole, 12.5 mg
metoprolol, and 2 mg midazolam) were administered alone
(baseline), after pretreatment with a combination of three
CYP inhibitors at clinically recommended doses (flucona-
zole 400-mg loading dose, followed by 200 mg per day,
ciprofloxacin 750 mg every 12 h, and paroxetine 20 mg
per day), and after CYP induction with rifampicin (600 mg
once daily for 7 days). All subjects first received the
baseline assessment (study period 1), followed by the two
assessments after CYP inhibition or CYP induction (study
periods 2 and 3) in a randomized order. After the baseline
assessment, wash-out time was 14 days, and between the
second and third study period, 21 days allowed sufficient
time for elimination of all probe drugs after CYP
inhibition.
CYP inhibitors were selected from a list of recom-
mended in vivo CYP inhibitors based on their inhibitory
potency [8]. Ciprofloxacin is a strong inhibitor (C5-fold
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increase in AUC or [80 % decrease in clearance) of
CYP1A2, fluconazole is a strong inhibitor of CYP2C19 and
a moderate inhibitor (C2 but\5-fold increase in AUC or
50–80 % decrease in clearance) of CYP2C9 and CYP3A4.
Paroxetine is a strong inhibitor of CYP2D6. For CYP2B6,
no strong inhibitors approved for human use are available
and paroxetine, which has been shown to be a CYP2B6
inhibitor in vitro [9], was used. Paroxetine is mainly
metabolized by CYP2D6 with minor metabolism by
CYP3A4 and CY1A2. As only minor pathways are inhib-
ited by fluconazole and ciprofloxacin, no relevant effects
on paroxetine exposure are expected. As all three CYP
inhibitors have the potential to increase the corrected QT
interval, 12-lead ECGs were recorded 1 h before and 2 and
12 h after probe drug intake.
Rifampicin is a strong inducer (C80 % decrease in
AUC) of CYP3A, a moderate inducer (50–80 % decrease
in AUC) of CYP2B6, 2C9, and 2C19, and a weak inducer
of CYP1A2 [3]. For CYP2D6, no inducer has been
described to date. Duration of pretreatment with CYP
inhibitors was selected to achieve more than 90 % of
steady-state concentrations before administration of the
cocktail probe drugs. Duration of pretreatment with
rifampicin was selected based on clinical data, indicating
that a significant inducing effect is reached after 7 days
[10].
Fluconazole and paroxetine were given in the morning
on days -3, -2, and -1, ciprofloxacin in the morning and
in the evening of day -1, and a last dose of each inhibitor
was given in the morning of the study day, 1 h before
administration of the phenotyping cocktail probe drugs.
Each treatment was investigated in the same group of 16
healthy male subjects.
Blood samples for pharmacokinetic analysis were col-
lected before dosing and 0.25, 0.50, 0.75, 1, 2, 3, 4, 6, 8,
12, 24, 48, and 72 h after drug administration from an
antecubital vein into ethylenediaminetetraacetic acid tubes.
The tubes were centrifuged (1500g for 10 min at 4 C) and
plasma was stored at -80 C until analysis. To assess
compliance of the study subjects with the CYP inhibitor
and inducer pretreatments, concentrations of ciprofloxacin,
paroxetine, fluconazole, and rifampicin were measured in
aliquots of the plasma samples collected for pharmacoki-
netic analysis. Oral fluid and dried blood spot samples were
collected at the same time points as the blood samples.
Results of these analyses will be presented elsewhere.
Pharmacodynamic assessments (heart rate, blood pressure,
sedation score) were performed at baseline and 1, 2, 4, 6,
and 12 h after drug administration. Subjects rated their
level of sedation on a visual analog scale with a range from
0, ‘‘not tired’’ to 10, ‘‘very tired’’. All adverse events
regardless of severity or relationship to the study drug were
documented throughout the study.
2.2 Study Drugs
Caffeine (Coffeinum N 0.2 g, Mylan Dura GmbH,
Darmstadt, Germany), efavirenz (Stocrin, Merck Sharp &
Dohme-Chibret AG, Opfikon, Switzerland), losartan
(Cosaar, Merck Sharp & Dohme-Chibret AG, Opfikon,
Switzerland), metoprolol (Belok ZOK, AstraZeneca AG,
Zug, Switzerland), omeprazole (Antramups, AstraZeneca
AG, Zug, Switzerland), midazolam (midazolam oral solu-
tion, 2 mg/mL, University Hospital Pharmacy, Basel,
Switzerland), ciprofloxacin (Ciproxin, 750 mg, Bayer
AG, Zurich, Switzerland), fluconazole (Diflucan, 200 mg,
Pfizer AG, Zurich, Switzerland), paroxetine (Deroxat,
20 mg, GlaxoSmithKline, Mu¨nchenbuchsee, Switzerland),
and rifampicin (Rimactan, 600 mg, Sandoz Pharmaceu-
ticals, Rotkreuz, Switzerland) were purchased through the
University Hospital Pharmacy, Basel, Switzerland.
2.3 Materials and Reagents
Caffeine-d9, ciprofloxacin, efavirenz-d4, 8-hydroxye-
favirenz, 8,14-dihydroxyefavirenz, fluconazole, losartan,
losartan carboxylic acid (E3174), losartan-d4, a-hydrox-
ymetoprolol, metoprolol-d7, omeprazole, 5-hydroxy-
omeprazole, omeprazole-d3, paroxetine, and rifampicin
were purchased from Toronto Research Chemicals (Tor-
onto, Canada). 1’-Hydroxymidazolam and midazolam-d6
were purchased from Lipomed (Lipomed AG, Arlesheim,
Switzerland). Metoprolol, paraxanthine, and b-glu-
curonidase were obtained from Sigma-Aldrich (Sigma-
Aldrich Chemie GmbH, Buchs, Switzerland). Midazolam
(Hoffmann-La Roche, Basel, Switzerland) and efavirenz
(Merck, NJ, USA) were kindly provided by the producers.
Formic acid, high-performance liquid chromatography
(HPLC)-grade methanol, and water were purchased from
Merck (Merck, Darmstadt, Germany). Stock solutions,
calibration spiking solutions, and quality controls were
prepared in dimethyl sulfoxide. Calibration standards were
prepared by enriching caffeine-free blank human serum
using the corresponding spiking solutions. Internal stan-
dard solutions containing the deuterated compounds were
prepared in methanol.
2.4 Bioanalysis
Concentrations of cocktail probe drugs and their main
metabolites as well as concentrations of the CYP inhibitors
ciprofloxacin, ketoconazole, paroxetine, and the CYP
inducer rifampicin in plasma samples were determined by
reversed phase HPLC tandem mass spectrometry as
described previously [7] with some modifications. Fifty
microliter aliquots of plasma were mixed with 150 lL
internal standard solution containing deuterated analogs of
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each of the six cocktail probe drugs at a concentration of
100 ng/mL, vortex mixed for 30 s, and centrifuged (3220g,
30 min, 10 C). Chromatographic separation was per-
formed on a Shimadzu HPLC system (Shimadzu AG,
Reinach, Switzerland) coupled to a triple quadrupole tan-
dem mass spectrometer (API4000, AB/MDS Sciex, Con-
cord, Canada) operating in positive electrospray ionization
mode, except for efavirenz and its metabolite, which were
detected in negative mode. Samples were eluted on an
Atlantis T3 column (2.1 9 50 mm, 3 lm, Waters, Baden-
Da¨ttwil, Switzerland). The injection volume was 10 lL
and total run time was 2.5 min. The following gradient was
applied: from 0 to 0.5 min 100 % solvent A (0.1 % formic
acid in water), from 0.5 to 2 min the proportion of solvent
B (0.1 % formic acid in methanol) linearly increased from
50 to 70 %, at 2.01 min, the percentage of B was increased
to 95 % and maintained for 0.5 min. At 2.5 min, the initial
conditions were re-established. The flow rate was 0.8 mL/
min, the column was placed in a column oven at 60 C, and
the samples were stored in the autosampler at 10 C. A
calibration curve was constructed, plotting analyte con-
centration vs. peak area ratios of the analyte/deuterated
internal standard measured in plasma standard samples.
Deuterated analogs of each cocktail probe drug were used
for the respective parent drug and metabolite. For flu-
conazole, paroxetine, ciprofloxacin, and rifampicin, mida-
zolam-d6 was used as the internal standard. Inter-assay
accuracy (determined as the percent bias) for plasma
quality control samples ranged from -11.6 to 10.2 % and
inter-assay precision (determined as the relative standard
deviation) was lower than 10.4 % for all analytes (Sup-
plementary Table 1). The lower limit of quantification was
0.5 ng/mL for a-hydroxymetoprolol, omeprazole, 5-hy-
droxyomeprazole, midazolam, 10-hydroxymidazolam, and
8,14-dihydroxyefavirenz, 1 ng/mL for metoprolol, losar-
tan, losartan carboxylic acid, efavirenz, 8-hydroxye-
favirenz, paroxetine, and rifampicin, 10 ng/mL for
paraxanthine and caffeine, 25 ng/mL for fluconazole, and
50 ng/mL for ciprofloxacin. Calibration ranges and
autosampler stability data are given in Supplementary
Tables 2 and 3. For all 10-hydroxymidazolam measure-
ments, 50-lL aliquots of plasma were incubated with 500
units of b-glucuronidase Type HP 2 (Sigma G7017, Sigma-
Aldrich, Buchs, Switzerland) at 37 C for 16 h. Further
sample processing was the same as described for not pre-
incubated plasma samples.
2.5 Data Analysis
Areas under the plasma concentration time curve (AUC)
from time 0 to 24 h after dosing (AUC24) or from time 0 to
the last quantifiable concentration if the last quantifiable
concentration was observed before 24 h after dosing were
estimated with non-compartmental methods using Phoenix
WinNonlin software (Certara, Princeton, NJ, USA). AUCs
after inhibition or induction were compared with baseline
AUCs for all parent drugs and their metabolites using a
WinNonlin average bioequivalence model. Correlations
between single time point metabolic ratios (i.e., parent drug
concentration over metabolite concentration, except for
CYP1A2 where the inverse ratio was used) and corre-
sponding AUCparent/AUCmetabolite ratios were analyzed
using Spearman’s rank correlations. AUCparent/AUCmetabo-
lite ratios and metabolic ratios after CYP inhibition and
CYP induction were compared with baseline ratios using
Wilcoxon signed rank tests with a corrected p\ 0.025 for
the two comparisons. Concentration ratios of extensive,
intermediate, and poor metabolizers were compared using
nonparametric Kruskal–Wallis tests. For CYP1A2, 2B6,
2C9, and 2C19 subjects with two wild-type alleles (*1A or
*1) and for CYP2D6 with at least one fully functional
allele (*1 or *2) were considered as extensive metabolizers
[11–15]. Pharmacodynamic parameters (heart rate, blood
pressure, sedation scores) were parametrized by calculating
area under the effect curves from time 0 to 12 h and ana-
lyzed using a one-way, repeated-measures analysis of
variance after testing for normal distribution. IBM SPSS
Statistics, version 21 (IBM Corporation, Armonk, NY,
USA) was used for statistical analyses.
2.6 Genotype Analysis
DNA was isolated from ethylenediaminetetraacetic acid
blood on an m2000sp instrument (Abbott Molecular, De
Plaines, IL, USA). Specific single nucleotide polymor-
phisms in the genes encoding CYP1A2 (alleles *1A, *1F),
CYP2B6 (allele*6), CYP2C9 (alleles *2, *3), CYP2C19
(alleles *2, *3), and CYP2D6 (alleles *3, *4, *6) were
detected using primer/probe real-time polymerase chain
reaction (PCR) reagents (Lightmix, TIB MOLBIOL, Ber-
lin, Germany) on a Lightcycler 1.5 instrument (Roche
Diagnostics, Rotkreuz, Switzerland) [16, 17]. For detection
of CYP2D6 allele *5 (gene deletion) and *XN (gene
duplication), a long-range PCR using the Expand Long
Template PCR system kit (Roche Diagnostics) was used.
For detection and confirmation of CYP2D6 rare alleles
(*41, *XN), hybridization of amplified products was per-
formed using the DNA chip technology (PharmaChip,
Progenika, Derio, Spain).
3 Results
Sixteen healthy male volunteers (mean age 23.8 years,
range 20–35 years, mean body mass index 23.5 kg/m2,
range 20.6–27.5 kg/m2) completed the study according to
82 A. Derungs et al.
the protocol. All subjects had no history of relevant disease
or drug abuse. All study subjects were of Caucasian eth-
nicity, with normal findings on physical examination,
normal screening laboratory tests (including screening for
drugs of abuse), and normal electrocardiograms. The phe-
notyping probe drugs of the Basel cocktail, as well as the
drugs used for CYP inhibition and induction were tolerated
without serious adverse events. No clinically or statistically
significant changes in heart rate, blood pressure, or seda-
tion scores compared with baseline were observed (Sup-
plementary Fig. 1). No clinically relevant changes of
electrocardiogram parameters were observed. After
administration of the CYP inhibitor cocktail, all corrected
QT intervals remained below 450 ms.
Compliance with the inhibitor and inducer pretreatment
was assessed by determination of the AUCs of cipro-
floxacin, paroxetine, fluconazole, and rifampicin (Supple-
mentary Fig. 2). All 16 study participants showed adequate
exposure to the three CYP inhibitors. However, data from
one study participant had to be excluded from analysis of
the induction data. This subject had rifampicin concentra-
tions approximately 100-fold higher compared with the
other subjects, either owing to an erroneous intake of
rifampicin shortly before application of the cocktail probe
drugs or non-compliance with the pretreatment regimen
and insufficient auto-induction of rifampicin metabolism.
The plasma concentration-time profiles for the six probe
drugs of the Basel cocktail and their metabolites are shown
in Fig. 1. Compared with baseline conditions, pretreatment
with the three CYP inhibitors increased the concentrations
of the parent probe drugs (except for CYP2B6) and
decreased the concentrations of their respective metabolites
(except for CYP3A4). Pretreatment with the CYP inducer
rifampicin had the opposite effect on the parent probe drug
concentrations (except for CYP2D6), while the concen-
trations of the metabolites only increased for CYP2B6. For
the other CYP isoforms, the metabolite concentrations after
induction were either unchanged or lower compared with
baseline.
Geometric mean AUC ratios and metabolic ratios for 2,
4, 6, and 8 h after probe drug administration for each CYP
isoform are shown in Table 1. AUC ratios after pretreat-
ment with CYP inhibitors were significantly different from
baseline AUC ratios for all CYP isoforms. After CYP
induction with rifampicin, a significant change of AUC
ratios was observed for all CYP isoforms except for
CYP2C9, where the losartan:E3174 AUC ratio did not
adequately reflect induced CYP activity.
The metabolic ratios in plasma were highly correlated
with the corresponding AUC ratios for most of the tested
time points (Table 2). The highest overall correlation
between metabolic ratios and AUC ratios for all three
conditions combined was found at 2 h after probe drug
administration for CYP3A4, at 4 h for CYP1A2 and
CYP2C19, and at 6 h for CYP2B6, CYP2C9, and CYP2D6.
Inhibition increased metabolic ratios (higher parent and
lower metabolite concentration) for all CYP isoforms
except for CYP1A2 (Fig. 2). For this isoform, the inverse
ratio (i.e., metabolite over parent concentration) was used
for better comparability with published data; and this
inverse ratio decreased compared with baseline. The effect
of CYP inhibition could be detected in almost every study
subject for all tested CYP isoforms. After CYP inhibition,
metabolic ratios were significantly different from baseline
for all tested time points (i.e., with data available for
inhibition and induction) for CYP1A2, 2B6, 2C9 (except
for the 2-h ratio), 2C19, and 2D6.
After CYP induction, metabolic ratios were significantly
different from baseline for all tested time points for
CYP1A2, 2B6, and 2C19 (Table 1; Fig. 3). For CYP2D6,
no consistent difference of metabolic ratios compared with
baseline was observed. Because of induced glucuronidation
of 10-hydroxymidazolam, which quantitatively outweighed
the induced formation of 10-hydroxymidazolam [18], the
metabolic ratio for CYP3A only was significantly different
from baseline when total 10-hydroxymidazolam concentra-
tions after pretreatment of samples with b-glucuronidase
were used. After deglucuronidation, total 10-hydroxymida-
zolam concentrations were approximately 8- to 10-fold
higher compared with 10-hydroxymidazolam concentrations
before deglucuronidation (Supplementary Table 4). In
contrast to CYP3A4, deglucuronidation did not improve
metabolic ratios for induction of CYP2B6 (data not shown).
The concentrations of 8,14-dihydroxy-efavirenz, a sec-
ondary CYP2B6-mediated metabolite of 8-hydroxye-
favirenz, were below the limit of quantification and lower
than 6 ng/mL after deglucuronidation. Therefore, this
dihydroxymetabolite was not considered for further
analyses.
One subject did not consent to genotype testing; all
other study participants were genotyped for the most
important altered-function alleles (Supplementary
Table 5). CYP2D6 genotyping identified one intermediate
metabolizer (IM) with a combination of a loss-of-function
and a diminished-function allele (CYP2D6*4/*41) and 14
extensive metabolizers (EM) with at least one fully func-
tional allele (*1 or *2) [15]. Without pre-treatment, the
CYP2D6 IM had a three-fold higher metabolic ratio at 6 h
compared with EMs (8.5 vs. median value of EMs 2.3).
Pretreatment with paroxetine increased the metabolic ratios
of all subjects regardless of genotype and increased meta-
bolic ratios of EM subjects to the range observed for the
non-inhibited IM (Fig. 2e).
For CYP2B6, no subject was homozygous and nine
subjects were heterozygous for a diminished-function
allele of CYP2B6 (CYP2B6*6). Although the subject with
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Fig. 1 Plasma concentration-time profiles of the Basel cocktail probe
drugs under baseline conditions (squares), after pretreatment with a
combination of CYP inhibitors (circles) and after pretreatment with
the CYP inducer rifampicin (diamonds). Concentration-time profiles
are shown for the probe drugs (closed symbols, solid lines) and their
respective metabolites (open symbols, dashed lines). a Caffeine and
paraxanthine (CYP1A2), b efavirenz and 8-hydroxyefavirenz
(CYP2B6), c losartan and losartan carboxylic acid (CYP2C9),
d omeprazole and 5-hydroxyomeprazole (CYP2C19), e metoprolol
and a-hydroxymetoprolol (CYP2D6), f midazolam and 10-hydrox-
ymidazolam (CYP3A4). Pretreatment with a combination of CYP
inhibitors significantly changed the pharmacokinetic profiles of all
probe drugs and their metabolites while the CYP inducer rifampicin
predominantly affected the probe drugs for CYP2B6, 2C19, and 3A4.
CYP cytochrome P450 enzyme
84 A. Derungs et al.
the highest baseline metabolic ratio was CYP2B6*6
heterozygous, there was no statistically significant differ-
ence between metabolic ratios of wild-type and *6
heterozygous subjects (Fig. 2b).
For CYP2C9, no subject was homozygous for a reduced
function allele (*2 or *3). One subject was heterozygous for
CYP2C9*2 and five subjects were heterozygous for
CYP2C9*3. Subjects heterozygous for the *3 haplotype had
higher metabolic ratios at 6 h, both at baseline (0.13–0.53),
and after inhibition (1.20–1.86), and in both conditions they
were higher than the metabolic ratios of the other subjects
(baseline 0.04–0.11, inhibition 0.20–0.53, Fig. 2c).
Table 1 AUC ratios and metabolic ratios after administration of cocktail probe drugs with and without inhibitors and inducer
CYP Metric Time (h) Cocktail alone Cocktail ? inhibitors Cocktail ? inducer
1A2 AUC24par/AUC24caf 0.63 (0.58–0.71) 0.38 (0.35–0.45)*** 0.64 (0.59–0.70)***
a
[par]/[caf] 2 0.32 (0.29–0.38) 0.13(0.11–0.20)***b 0.38 (0.35–0.44)***a
[par]/[caf] 4 0.46 (0.41–0.55) 0.21 (0.18–0.27)*** 0.57 (0.52–0.64)***a
[par]/[caf] 6 0.64 (0.58–0.79) 0.30 (0.26–0.38)***a 0.78 (0.72–0.89)***a
[par]/[caf] 8 0.80 (0.71–0.97) 0.39 (0.35–0.49)*** 0.96 (0.87–1.13)***a
2B6 AUC24efa/ AUC24OH-efa 41.7 (37.9–48.2) 73.9 (62.2–99.1)*** 21.1 (19.7–23.2)***
a
[efa]/[OH-efa] 2 23.7 (21.1–29.0) 51.2 (43.3–70.0)***b 12.8 (10.7–15.0)***a
[efa]/[OH-efa] 4 38.7 (34.8–48.5) 84.1 (71.9–115.0)*** 19.3 (17.9–21.3)***a
[efa]/[OH-efa] 6 43.7 (39.5–51.3) 77.6 (69.3–94.2)***a 23.1 (21.3–25.7)***a
[efa]/[OH-efa] 8 53.2 (47.8–62.6) 88.7 (79.7–108.0)*** 27.7 (26.0–30.8)***a
2C9 AUClos/AUCE3174 0.09 (0.06–0.15) 0.24 (0.19–0.41)*** 0.07 (0.06–0.11)nsa
[los]/[E3174] 2 1.18 (1.17–2.99) 3.39 (2.66–4.62)nsf 0.44 (0.37–0.96)**b
[los]/[E3174] 4 0.17 (0.14–0.37) 1.17 (1.03–2.09)*** 0.08 (0.06–0.16)**a
[los]/[E3174] 6 0.10 (0.08–0.19) 0.55 (0.47–1.01)***a 0.06 (0.04–0.12)***c
[los]/[E3174] 8 0.05 (0.04–0.08) 0.24 (0.20–0.42)*** 0.05 (0.04–0.07) nsb
2C19 AUCome/AUCOH-ome 0.89 (0.76–1.17) 17.9 (16.0–21.3)*** 0.22 (0.19–0.30)***a
[ome]/[OH-ome] 2 1.08 (0.90–1.46) 25.8 (22.7–33.2)*** 0.25 (0.22–0.35)**a
[ome]/[OH-ome] 4 0.49 (0.38–0.86) 18.1 (16.0–22.5)*** 0.18 (0.15–0.24)***a
[ome]/[OH-ome] 6 0.28 (0.18–0.55)b 14.6 (12.5–18.8)nta na
[ome]/[OH-ome] 8 na na na
2D6 AUC24met/ AUC24OH-met 1.69 (1.54–1.93) 7.57 (5.48–10.89)*
g 1.45 (1.34–1.62)***b
[met]/[OH-met] 2 1.93 (1.56–2.47)e na 1.83 (1.60–2.18) ntd
[met]/[OH-met] 4 2.20 (2.00–2.54) 6.60 (5.90–7.85)*** 2.02 (1.84–2.31) nsa
[met]/[OH-met] 6 2.36 (2.16–2.69)a 8.99 (8.33–10.01)*** 1.88 (1.69–2.20)*a
[met]/[OH-met] 8 2.11 (1.91–2.44) 9.90(9.06–11.39)*** 1.67 (1.51–1.93) nsb
3A4 AUCmid/AUC1-OH-mid 1.55 (1.36–2.08) 4.44 (3.92–5.67)*** 3.89 (3.30–7.87)**a
[mid]/[OH-mid] 2 1.31 (1.16–1.77) 3.46 (3.10–4.29)*** 1.73 (1.54–2.11) nsa
[mid]/[OH-mid] 4 1.51 (1.33–1.97) 3.81 (3.43–4.58)nt na
[mid]/[OH-mid] 6 1.64 (1.35–2.31)c 4.50 (3.94–5.60)nta na
[mid]/[OH-mid] 8 na na na
3A4 degluc AUCmid/AUCOH-mid tot 0.16 (0.14–0.21) 0.61 (0.54–0.79)*** 0.04 (0.03–0.05)***a
[mid]/[OH-mid]tot 2 0.17 (0.15–0.25) 0.64 (0.56–0.85)*** 0.06 (0.06–0.08)***a
[mid]/[OH-mid]tot 4 0.20 (0.18–0.27) 0.67 (0.59–0.86)*** 0.14 (0.06–0.23) nsh
[mid]/[OH-mid]tot 6 0.18 (0.15–0.26) 0.65 (0.59–0.78)nta na
[mid]/[OH-mid]tot 8 na na na
Data are presented as geometric mean ratios with 90 % confidence intervals
AUC area under plasma concentration-time curve from time 0 to last measurable concentration, AUC24 area under the plasma concentration-time
curve from time 0 to 24 h, caf caffeine, E3174 losartan carboxylic acid, efa efavirenz, los losartan, met metoprolol, mid midazolam, na not
available, ns not significant, nt not tested, OH-efa 8-hydroxyefavirenz, OH-mid 10-hydroxymidazolam, OH-mid tot total 10-hydroxymidazolam
concentration after deglucuronidation, OH-met a-hydroxymetoprolol, OH-ome 5-hydroxyomeprazole, par paraxanthine
* p\ 0.025; ** p\ 0.01; *** p\ 0.001 (Wilcoxon signed rank test)
N = 16 unless indicated otherwise: a n = 15; b n = 14; c n = 13; d n = 10; e n = 8; f n = 7; g n = 6; h n = 3
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CYP2C19 genotyping identified one poor metabolizer
(CYP2C19 *2/*2) and four intermediate metabolizers
(CYP2C19 *1/*2). At baseline, the subject with the poor
metabolizer genotype had the highest 4-h metabolic ratio
(17.6, Fig. 2d), whereas the metabolic ratios of the IMs
(0.5–1.7) did not differ from the metabolic ratios of the
EMs (0.2–2.0) with two wild-type alleles (*1/*1).
Four subjects were homozygous and 10 subjects
heterozygous for CYP1A2*1F. There was no correlation
between genotype and metabolic ratios after induction with
rifampicin (data not shown).
4 Discussion
In this study, we characterized our previously described
phenotyping cocktail in subjects with inhibited or induced
CYP activity. Independent of CYP activity, the cocktail
was well tolerated and no clinically or statistically signif-
icant effects on cardiovascular function or vigilance of the
subjects were observed.
Pretreatment with the three CYP inhibitors cipro-
floxacin, fluconazole, and paroxetine had a clearly detect-
able effect on metabolic ratios for all six CYP isoforms and
Table 2 Spearman rank correlations between AUC ratios and metabolic ratios at different time points after cocktail administration without and
with inhibitors or inducer
CYP Metric Time (h) All conditions Cocktail alone Cocktail ? inhibitors Cocktail ? inducer
qs p value qs p value qs p value qs p value
1A2 [par]/[caf] 2 0.917 \0.001 0.797 \0.001 0.721 0.002 0.900 \0.001a
[par]/[caf] 4 0.935 <0.001 0.956 <0.001 0.932 <0.001 0.804 <0.001a
[par]/[caf] 6 0.918 \0.001 0.906 \0.001 0.893 \0.001a 0.743 0.002a
[par]/[caf] 8 0.923 \0.001 0.838 \0.001 0.853 \0.001 0.750 0.002a
2B6 [efa]/[OH-efa] 2 0.911 \0.001 0.559 0.024 0.719 0.004b 0.636 0.011a
[efa]/[OH-efa] 4 0.942 \0.001 0.876 \0.001 0.762 0.001 0.518 0.048a
[efa]/[OH-efa] 6 0.975 <0.001 0.850 <0.001 0.771 0.001a 0.871 <0.001a
[efa]/[OH-efa] 8 0.965 \0.001 0.812 \0.001 0.788 \0.001 0.729 0.002a
2C9 [los]/[E3174] 2 0.683 \0.001 0.706 0.002 0.429 0.004f 0.380 nsb
[los]/[E3174] 4 0.840 \0.001 0.762 0.001 0.529 0.035 0.589 0.021a
[los]/[E3174] 6 0.871 <0.001 0.812 <0.001 0.754 0.001a 0.602 0.017a
[los]/[E3174] 8 0.848 \0.001 0.674 0.004 0.679 0.004 0.613 0.020b
2C19 [ome]/[OH-ome] 2 0.954 \0.001 0.853 \0.001 0.156 ns 0.936 \0.001a
[ome]/[OH-ome] 4 0.959 <0.001 0.942 <0.001 0.774 <0.001 0.546 <0.001a
[ome]/[OH-ome] 6 0.925 \0.001b 0.886 \0.001a na
[ome]/[OH-ome] 8 na na na
2D6 [met]/[OH-met] 2 0.048 nse na 0.564 nsd
[met]/[OH-met] 4 0.873 \0.001 0.815 \0.001 0.657 nsg 0.736 0.003b
[met]/[OH-met] 6 0.879 <0.001 0.682 0.005a 0.829 0.042g 0.820 <0.001b
[met]/[OH-met] 8 0.866 \0.001 0.650 0.006 1.000 \0.001g 0.864 \0.001b
3A4 [mid]/[OH-mid] 2 0.962 \0.001 0.965 \0.001 0.743 0.002a
[mid]/[OH-mid] 4 0.697 0.003 0.909 \0.001 na
[mid]/[OH-mid] 6 0.687 0.01c 0.796 \0.001a na
[mid]/[OH-mid] 8 na na na
3A4 degluc [mid]/[OH-mid]tot 2 0.968 <0.001 0.921 <0.001 0.791 <0.001 0.664 0.007a
[mid]/[OH-mid]tot 4 0.969 \0.001 0.900 \0.001 0.885 \0.001 0.500 0.667h
[mid]/[OH-mid]tot 6 0.894 \0.001 0.811 \0.001a na
[mid]/[OH-mid]tot 8 na na na
Time points with the highest overall correlation between AUC ratios and metabolic ratios are highlighted in bold
AUC area under plasma concentration-time curve from time 0 to last measurable concentration, caf caffeine, E3174 losartan carboxylic acid, efa
efavirenz, los losartan, met metoprolol, mid midazolam, na not available, ns not significant, OH-efa 8-hydroxyefavirenz, OH-mid 10-hydrox-
ymidazolam, OH-mid tot total 10-hydroxymidazolam concentration after deglucuronidation, OH-met a-hydroxymetoprolol, OH-ome 5-hy-
droxyomeprazole, par paraxanthine, qs Spearman’s correlation coefficient
N = 16 unless indicated otherwise: a n = 15; b n = 14; c n = 13; d n = 10; e n = 8; f n = 7; g n = 6; h n = 3
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caused an intra-individual change of the metabolic ratio in
almost every study subject.
In contrast to inhibition, CYP induction could not be
detected for all the rifampicin-inducible CYP isoforms. For
CYP2C9, the losartan:E3174 ratio in plasma did not reflect
induction. This is in contrast to the situation in urine where
pretreatment with rifampicin causes a significant decrease
in the losartan:E3174 ratio [3]. The reason for the different
Fig. 2 Intra-individual change of metabolic ratios of the Basel
cocktail probe drugs after pretreatment with the CYP inhibitors
ciprofloxacin, paroxetine, and fluconazole compared with baseline.
CYP inhibition changed the metabolic ratio in every single subject for
CYP1A2 (a), CYP2B6 (b), CYP2C9 (c), CYP2C19 (d), CYP2D6 (e),
and CYP3A4 (f). Metabolic ratios of subjects with altered function
alleles are shown using open symbols. The CYP2C19 poor metab-
olizer (CYP2C19*2/*2), the CYP2D6 intermediate metabolizer
(CYP2D6*4/*41) and subjects heterozygous for the CYP2C9*3 allele
had higher metabolic ratios at baseline compared with extensive
metabolizer subjects. CYP cytochrome P450 enzyme
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behavior of the losartan:E3174 ratio in plasma is that
rifampicin not only decreased concentrations of losartan,
but also of the E3174 metabolite, most likely by enhancing
its further elimination from plasma [21]. The exact
pathway of E3174 elimination has not been described.
Further metabolism by UDP glucuronosyl transferases has
been suggested [21]; however, we did not find an increase
in E3174 concentrations after deglucuronidation. Another
Fig. 3 Intra-individual change of metabolic ratios of the Basel
cocktail probe drugs after pretreatment with the CYP inducer
rifampicin compared with baseline. A consistent increase of
metabolic ratios was observed for CYP1A2 (except for three subjects)
(a), and a consistent decrease for CYP2B6 (except for one subject)
(b), CYP2C19 (d), and CYP3A4 after deglucuronidation (f). The
metabolic ratios of CYP2C9 (c), and CYP2D6 (e) only showed small
and inconsistent changes after induction. Metabolic ratios of subjects
with altered function alleles are shown using open symbols. CYP
cytochrome P450 enzyme
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mechanism could be increased elimination by induced
efflux pumps. While losartan is transported by p-glyco-
protein (pgp), E3174 is not a pgp substrate. There is evi-
dence, however, that other efflux transporters than pgp
could be involved in the elimination of E3174 [22]. This is
supported by the observation that rifampicin pretreatment
increases concentrations of E3174 in urine [3, 4] (and
thereby decreases the losartan:E3174 ratio). As there is no
easy procedure such as deglucuronidation to assess the
total amount of E3174 produced by induced CYP2C9, the
losartan:E3174 ratio cannot be recommended for CYP2C9
phenotyping in plasma. Several alternative probe drugs,
such as flurbiprofen, warfarin, or phenytoin can be used for
CYP2C9 phenotyping. While warfarin and phenytoin have
a narrow therapeutic range and require collection of mul-
tiple samples [19, 20], flurbiprofen allows limited and
minimally invasive sampling strategies [5].
For CYP3A4, the simple midazolam:10-hydroxymida-
zolam ratio showed no relevant change after induction
because 10-hydroxymidazolam is further metabolized by
UDP glucuronosyl transferases and this phase II reaction is
also induced by rifampicin. After induction, glucuronida-
tion may even exceed formation of 10-hydroxymidazolam
and lead to similar metabolic ratios as seen after CYP3A4
inhibition [4]. Therefore, a metabolic ratio that includes
both products of the two sequential and inducible reactions
will more adequately reflect induction [18]. Because direct
quantification of 10-hydroxymidazolam-glucuronide is dif-
ficult, an indirect method was used and samples were
pretreated with b-glucuronidase to allow quantification of
the total amount of 10-hydroxymidazolam produced by the
induced CYP3A4. Metabolic ratios using total 10-hydrox-
ymidazolam concentrations then adequately reflected
induced CYP3A4 activity in every study subject. For
CYP2B6, however, the efavirenz:8-hydroxyefavirenz ratio
without deglucuronidation was sufficient to detect
induction.
Induction of CYP1A2 is mediated by the aryl hydro-
carbon receptor, which is activated by polycyclic aromatic
hydrocarbons and, in contrast to other CYP isoforms,
rifampicin only has a weak inducing effect on CYP1A2
[21, 22]. Correspondingly, we only found a small increase
in metabolic ratios, which is in line with previous obser-
vations [3, 5].
CYP2D6 is considered to be a non-inducible CYP iso-
form and no effects on CYP2D6 phenotyping metrics have
been found or reported in previous induction studies [4, 5].
In our study, we found a small decrease of the metopro-
lol:a-hydroxymetoprolol AUC ratio and an inconsistent
decrease of metabolic ratios at different time points.
Although a-hydroxylation of metoprolol is mainly medi-
ated by CYP2D6, formation of a-hydroxymetoprolol by an
induced CYP isoform other than CYP2D6 could explain
this finding. However, as phenotyping of CYP2D6 is
focused on inhibition, which is reliably detected with
metoprolol, this does not limit the usefulness of this probe
drug for CYP2D6 phenotyping.
Metabolic ratios of the two subjects that were either
homozygous for loss-of-function alleles (CYP2C19*2/*2)
or had a combination of a reduced function and a loss-of-
function allele (CYP2D6*4/*41) were distinctly higher
than metabolic ratios of the other subjects. For the
CYP2D6 IM subject, the metabolic ratio was almost the
same as the one we found in another subject with the
identical genotype in our first cocktail study [7], and it can
be expected that subjects with very low metabolic activity
of these CYP isoforms can easily be identified with this
cocktail. Interestingly, we also found higher losar-
tan:E3174 ratios in plasma for CYP2C9*1/*3 subjects
compared with wild-type subjects. This is in line with
previous observations where losartan:E3174 ratios in urine
also were higher in subjects with the same genotype [23,
24]. However, as already observed in our first study [7],
metabolic ratios of subjects only heterozygous for a
reduced function allele may also considerably overlap with
metabolic ratios of wild-type subjects.
In a recently published cocktail, the same probe drugs
for CYP1A2, CYP2C19, and CYP3A4 were used as in our
cocktail, while bupropion, flurbiprofen, and dex-
tromethorphan were chosen for CYP2B6, CYP2C9, and
CYP2D6, respectively [5]. For bupropion, the absence of
an inhibitory effect on CYP2D6 is suggested based on
in vitro data and theoretical considerations. For efavirenz,
the only other sensitive CYP2B6 substrate listed by the US
Food and Drug Administration and the European Medici-
nes Agency besides bupropion, we provided in vivo data
demonstrating the lack of interaction with the other com-
ponents of our cocktail [7]. A common disadvantage for
both CYP2B6 probe drugs is their long half-life of
50–70 h, which prolongs wash-out periods when they are
used as probe drugs in clinical studies with crossover
designs.
Our study has several limitations. While characteriza-
tion of phenotyping metrics for inhibited and induced CYP
activity is an important validation criterion, further vali-
dation work is needed. Our study population consisted of
young healthy male subjects. While this selection reduces
confounding factors, it limits generalizability of the study
results to other populations, e.g., female or elderly subjects,
which will need to be tested in separate studies. Although
the CYP inhibitors and the inducer are recommended
compounds for in vivo drug interaction studies, they do not
have a strong inhibiting or inducing effect on all the tested
CYP isoforms. Therefore, the changes of the phenotyping
metric likely will be more pronounced when more potent
in vivo inhibitors or inducers can be tested. Another
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limitation is the failure of losartan to reliably indicate
CYP2C9 induction, necessitating a modification of the
cocktail composition with an alternative probe drug for
CYP2C9.
5 Conclusions
With this study we provide extensive data for the pheno-
typing metrics of the Basel cocktail in subjects with
inhibited and induced CYP activity. Obtaining such data is
an important step in the ongoing validation process of a
new phenotyping cocktail. While CYP inhibition could be
reliably detected for all CYP isoforms in almost every
study subject, detection of CYP induction was more
challenging. The losartan:E3174 AUC ratio in plasma did
not adequately reflect induced CYP2C9 activity. For
CYP3A4, induced CYP activity only was adequately
reflected by metabolic ratios using total 10-hydroxymida-
zolam concentrations. Although metabolic ratios after
CYP inhibition and induction overlap with baseline ratios
for many CYP isoforms, intra-individual changes of
metabolic ratios are sensitive indicators of altered CYP
activity and therefore represent valuable tools for drug–
drug interaction studies. The metabolic ratios need to be
confirmed for extensive metabolizers, and typical ratios
for subjects with genetically altered CYP activity have to
be established in separate studies. This will provide
important information for future clinical applications of
this phenotyping cocktail.
Acknowledgments The authors thank Claudia Blasi and Luisa
Baselgia for their assistance with the clinical study and Beatrice
Vetter for technical assistance.
Compliance with ethical standards This study was funded by the
Division of Clinical Pharmacology and Toxicology, University
Hospital Basel.
Christoph Noppen is an employee of Viollier AG, a provider of
commercial clinical laboratory services. Adrian Derungs, Massimil-
iano Donzelli, Benjamin Berger, Stephan Kra¨henbu¨hl, and Manuel
Haschke have no potential conflicts of interest to declare.
The study was approved by the local ethics committee (Ethikkom-
mission Basel) and the national regulatory authorities (Swiss Agency
for Therapeutic Products, Swissmedic) and conducted in accordance
with the ethical standards of the Declaration of Helsinki. Informed
consent was obtained from all individual participants included in the
study.
Author contributions Massimiliano Donzelli: designed research,
analyzed data, wrote the manuscript.
Adrian Derungs: designed research, performed research, wrote the
manuscript.
Benjamin Berger: performed research.
Christoph Noppen: contributed analytical tools, analyzed data.
Stephan Kra¨henbu¨hl: designed research, analyzed data.
Manuel Haschke: designed research, analyzed data, wrote the
manuscript.
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
References
1. Wilkinson GR. Drug metabolism and variability among patients
in drug response. N Engl J Med. 2005;352(21):2211–21 (Epub
2005/05/27).
2. Schellens JH, van der Wart JH, Brugman M, Breimer DD.
Influence of enzyme induction and inhibition on the oxidation of
nifedipine, sparteine, mephenytoin and antipyrine in humans as
assessed by a ‘‘cocktail’’ study design. J Pharmacol Exp Ther.
1989;249(2):638–45 (Epub 1989/05/01).
3. Kanebratt KP, Diczfalusy U, Backstrom T, Sparve E, Bredberg E,
Bottiger Y, et al. Cytochrome P450 induction by rifampicin in
healthy subjects: determination using the Karolinska cocktail and
the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clin
Pharmacol Ther. 2008;84(5):589–94 (Epub 2008/07/25).
4. Inui N, Akamatsu T, Uchida S, Tanaka S, Namiki N, Karayama
M, et al. Chronological effects of rifampicin discontinuation on
cytochrome P450 activity in healthy Japanese volunteers, using
the cocktail method. Clin Pharmacol Ther. 2013;94(6):702–8
(Epub 2013/08/27).
5. Bosilkovska M, Samer CF, Deglon J, Rebsamen M, Staub C,
Dayer P, et al. Geneva cocktail for cytochrome P450 and
P-glycoprotein activity assessment using dried blood spots. Clin
Pharmacol Ther 2014;96(3):349–59 (Epub 2014/04/12).
6. Branch RA, Adedoyin A, Frye RF, Wilson JW, Romkes M.
In vivo modulation of CYP enzymes by quinidine and rifampin.
Clin Pharmacol Ther. 2000;68(4):401–11 (Epub 2000/11/04).
7. Donzelli M, Derungs A, Serratore MG, Noppen C, Nezic L,
Krahenbuhl S, et al. The basel cocktail for simultaneous pheno-
typing of human cytochrome P450 isoforms in plasma, saliva and
dried blood spots. Clin Pharmacokinet. 2014;53(3):271–82
(Epub 2013/11/13).
8. Guidance for industry. Drug interaction studies—study design,
data analysis, implications for dosing, and labeling recommen-
dations. Center for Drug Evaluation and Research. Food and
Drug Administration, Silver Spring, MD. http://www.fda.gov/
downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/UCM292362.pdf.
9. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan
SX, Shader RI, et al. CYP2B6mediates the in vitro hydroxylation of
bupropion: potential drug interactions with other antidepressants.
Drug Metab Dispos. 2000;28(10):1176–83 (Epub 2000/09/21).
10. Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically
reduces plasma concentrations and effects of oral midazolam.
Clin Pharmacol Ther. 1996;59(1):7–13 (Epub 1996/01/01).
11. Thorn CF, Aklillu E, Klein TE, Altman RB. PharmGKB sum-
mary: very important pharmacogene information for CYP1A2.
Pharmacogenet Genomics. 2012;22(1):73–7 (Epub 2011/10/13).
12. Thorn CF, Lamba JK, Lamba V, Klein TE, Altman RB.
PharmGKB summary: very important pharmacogene information
for CYP2B6. Pharmacogenet Genomics. 2010;20(8):520–3
(Epub 2010/07/22).
13. Van Booven D, Marsh S, McLeod H, Carrillo MW, Sangkuhl K,
Klein TE, et al. Cytochrome P450 2C9-CYP2C9. Pharmacogenet
Genomics. 2010;20(4):277–81 (Epub 2010/02/13).
90 A. Derungs et al.
14. Scott SA, Sangkuhl K, Shuldiner AR, Hulot JS, Thorn CF, Alt-
man RB, et al. PharmGKB summary: very important pharma-
cogene information for cytochrome P450, family 2, subfamily C,
polypeptide 19. Pharmacogenet Genomics. 2012;22(2):159–65
(Epub 2011/10/27).
15. Owen RP, Sangkuhl K, Klein TE, Altman RB. Cytochrome P450
2D6. Pharmacogenet Genomics. 2009;19(7):559–62 (Epub
2009/06/11).
16. Cayan F, Ayaz L, Aban M, Dilek S, Gumus LT. Role of
CYP2C19 polymorphisms in patients with endometriosis.
Gynecol Endocrinol. 2009;25(8):530–5 (Epub 2009/06/06).
17. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer
UA, Goldstein JA. The major genetic defect responsible for the
polymorphism of S-mephenytoin metabolism in humans. J Biol
Chem. 1994;269(22):15419–22 (Epub 1994/06/03).
18. Link B, Haschke M, Grignaschi N, Bodmer M, Aschmann YZ,
Wenk M, et al. Pharmacokinetics of intravenous and oral mida-
zolam in plasma and saliva in humans: usefulness of saliva as
matrix for CYP3A phenotyping. Br J Clin Pharmacol.
2008;66(4):473–84 (Epub 2008/06/10).
19. Caraco Y, Muszkat M, Wood AJ. Phenytoin metabolic ratio: a
putative marker of CYP2C9 activity in vivo. Pharmacogenetics.
2001;11(7):587–96 (Epub 2001/10/23).
20. Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL,
Sellers E, et al. Combined phenotypic assessment of cytochrome
p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and
xanthine oxidase activities with the ‘‘Cooperstown 5 ? 1 cock-
tail’’. Clin Pharmacol Ther. 2003;74(5):437–47 (Epub 2003/10/
31).
21. Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore
JT, Kliewer SA. Nuclear pregnane x receptor and constitutive
androstane receptor regulate overlapping but distinct sets of genes
involved in xenobiotic detoxification. Mol Pharmacol.
2002;62(3):638–46 (Epub 2002/08/16).
22. Backman JT, Granfors MT, Neuvonen PJ. Rifampicin is only a
weak inducer of CYP1A2-mediated presystemic and systemic
metabolism: studies with tizanidine and caffeine. Eur J Clin
Pharmacol. 2006;62(6):451–61 (Epub 2006/06/08).
23. Yasar U, Dahl ML, Christensen M, Eliasson E. Intra-individual
variability in urinary losartan oxidation ratio, an in vivo marker
of CYP2C9 activity. Br J Clin Pharmacol. 2002;54(2):183–5
(Epub 2002/09/05).
24. Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena
A, Sjoqvist F, et al. Pharmacokinetics of losartan and its
metabolite E-3174 in relation to the CYP2C9 genotype. Clin
Pharmacol Ther. 2002;71(1):89–98 (Epub 2002/02/02).
Effects of CYP Inhibition and Induction on the Basel Cocktail 91
